STOCK TITAN
  1. Home
  2. News
  3. CVM

Cel-Sci Corporation - CVM STOCK NEWS

Welcome to our dedicated page for Cel-Sci Corporation news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on Cel-Sci Corporation stock.

Cel-Sci Corporation (symbol: CVM) is at the forefront of biotechnology, dedicated to advancing immunotherapy solutions for cancer and infectious diseases. Established in 1983 and headquartered in Vienna, Virginia, Cel-Sci is committed to harnessing the power of the human immune system to combat a variety of health challenges.

The company's leading investigational immunotherapy, Multikine (Leukocyte Interleukin, Injection), is currently in Phase III clinical trials for the treatment of head and neck cancer. This breakthrough therapy aims to improve survival rates by leveraging the body's natural defenses.

In addition to Multikine, Cel-Sci is pioneering the Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process designed to stimulate the immune system to fight bacterial, viral, and parasitic infections, and conditions such as autoimmune diseases, allergies, transplantation rejections, and cancer. Their innovative pipeline includes LEAPS-H1N1-DC, as well as product candidates CEL-2000 and CEL-4000 for the treatment of rheumatoid arthritis. The company is also developing LEAPS COV-19 to address the COVID-19 pandemic, in collaboration with the University of Georgia's Center for Vaccines and Immunology.

Cel-Sci's core capabilities extend to drug discovery, research, development, and the manufacturing of complex biological substances. The company's multifaceted approach not only targets cancer but also seeks to provide solutions for a wide range of infectious and autoimmune diseases. By focusing on these areas, Cel-Sci aims to deliver groundbreaking treatments that can significantly improve patient outcomes and quality of life.

Recent achievements and ongoing projects underscore Cel-Sci's commitment to innovation and excellence in the biotechnology field. The company's robust pipeline and strategic collaborations position it as a significant player in the quest for effective immunotherapies, offering hope to millions affected by cancer and other debilitating conditions.

Stay updated with the latest news and developments from Cel-Sci Corporation to track their progress and breakthroughs in cancer and immunotherapy research.

News

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

Rhea-AI Summary
CEL-SCI Corporation (CVM) announces a public offering of 3,875,000 shares of common stock at $2.00 per share, aiming to raise $7.75 million for further development of Multikine and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
offering
-
News

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

Rhea-AI Summary
CEL-SCI Corporation completes the commissioning of its Multikine manufacturing facility, a key step in preparing for regulatory approval for the treatment of head and neck cancer. The facility has been expanded and upgraded in anticipation of filing a Biologics License Application with the FDA and other regulators. This achievement signifies a significant milestone in bringing Multikine to market, and the company's CEO emphasizes the high value of their manufacturing trade secret, capability, and know-how.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
-
News

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) has received a product-specific waiver from the European Medicines Agency (EMA) Paediatric Committee, allowing them to commercialize their cancer immunotherapy Multikine in the European Union. This waiver is a significant step forward for the company, as it eliminates a major hurdle in their path towards commercialization in Europe. The waiver ensures that the company does not face delays in their plans for commercialization. The EU Paediatric Regulation, enacted in 2007, aims to strengthen the investigation and development of medicinal products for the pediatric population. This regulatory change has a direct impact on CEL-SCI's ability to bring Multikine to the market in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
News

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. The company identified the target head and neck cancer patient population for Multikine, which saw a 73% survival rate vs 45% in the control at 5 years. The UK's National Institute for Health and Care Excellence (NICE) selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck. Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression. Financially, research and development expenses decreased by 11% and general and administrative expenses decreased by 16%. Net loss narrowed by 12% to approximately $32.2 million for the twelve months ended September 30, 2023 from $36.7 million in fiscal 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
earnings
-
News

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Rhea-AI Summary
CEL-SCI Corporation (CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.27%
Tags
none
-
News

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

Rhea-AI Summary
CEL-SCI Corporation (CVM) Announces Closing of $5 Million Public Offering for Cancer Immunotherapy Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
offering
News

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

Rhea-AI Summary
CEL-SCI Corporation (CVM) announced the pricing of an offering of 2,490,000 shares of its common stock at $2.00 per share, generating gross proceeds of approximately $5 million. The net proceeds will be used for the development of Multikine, general corporate purposes, and working capital. The offering is expected to close on November 20, 2023. ThinkEquity is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.57%
Tags
offering
-
News

CEL-SCI Issues Letter to Shareholders

Rhea-AI Summary
CEL-SCI Corporation releases a shareholder letter from CEO Geert Kersten, detailing the efficacy of Multikine in head and neck cancer patients and plans for regulatory approval. The letter highlights the well-defined target population, the pre-surgical responses caused by Multikine, and the outstanding survival benefit. CEL-SCI believes they meet the necessary factors for approval and are eager to move forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none
-
News

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

Rhea-AI Summary
CEL-SCI Corporation releases video presentation on the impact of recent data on their immunotherapy drug Multikine for the treatment of advanced squamous cell carcinoma of the head and neck.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
clinical trial
News

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Rhea-AI Summary
CEL-SCI Corporation has finalized the selection criteria for the head and neck cancer target population to be treated with its immunotherapy drug Multikine. The target population consists of patients with low PD-L1 expression. The data from the Phase 3 trial showed a 28% 5-year absolute survival advantage for Multikine-treated patients compared to the control group. CEL-SCI plans to seek immediate approval for commercial distribution without waiting for completion of a confirmatory study in this target population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.12%
Tags
none

FAQ

What is the current stock price of Cel-Sci Corporation (CVM)?

The current stock price of Cel-Sci Corporation (CVM) is $0.5602 as of November 15, 2024.

What is the market cap of Cel-Sci Corporation (CVM)?

The market cap of Cel-Sci Corporation (CVM) is approximately 36.0M.

What is Cel-Sci Corporation's main focus?

Cel-Sci Corporation focuses on the research and development of immunotherapy for treating cancer and infectious diseases.

What is Multikine?

Multikine is Cel-Sci's lead investigational immunotherapy, currently in Phase III clinical trials for head and neck cancer.

What is the LEAPS technology?

LEAPS is a patented T-cell modulation process that stimulates the immune system to fight various infections and diseases, including cancer.

What other products is Cel-Sci developing?

Cel-Sci is also developing LEAPS-H1N1-DC, CEL-2000, CEL-4000 for rheumatoid arthritis, and LEAPS COV-19 for COVID-19.

Where is Cel-Sci Corporation headquartered?

Cel-Sci Corporation is headquartered in Vienna, Virginia.

When was Cel-Sci Corporation founded?

Cel-Sci Corporation was founded in 1983.

With whom does Cel-Sci collaborate for LEAPS COV-19?

Cel-Sci collaborates with the University of Georgia's Center for Vaccines and Immunology for LEAPS COV-19.

What areas does Cel-Sci's research cover?

Cel-Sci's research covers cancer, autoimmune diseases, allergies, transplantation rejections, bacterial, viral, and parasitic infections.

What are CEL-2000 and CEL-4000?

CEL-2000 and CEL-4000 are Cel-Sci's product candidates for the treatment of rheumatoid arthritis.

What distinguishes Cel-Sci in the biotechnology sector?

Cel-Sci's unique approach involves leveraging the immune system to devise treatments for cancer and other serious diseases, supported by its robust pipeline and strategic collaborations.

Stock CVM logo
Cel-Sci Corporation

NYSE:CVM

CVM Rankings

#5027 Ranked by Market Cap
N/A Ranked by Dividends

CVM Stock Data

35.96M
63.81M
2.92%
10.38%
6.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
VIENNA